Stock listing
BOATS:CCCC C4 Therapeutics, Inc. Stock
US listing (BOATS) of C4 Therapeutics, Inc. · home listing NASDAQ:CCCC
Follow C4 Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CCCC
$3.37 USD +0.07 (+2.1%)
Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CCCC
- Day range
- $3.21 – $3.38 USDOct 30, 2026
- Volume
- 2.35M sharesOct 30, 2026
- Market cap
- $414.6M USDAt the close on Oct 30, 2026 · price × 123.0M shares outstanding
- 52-week range
- $1.69 – $5.17 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $8.34M USDMedian day 2.26M shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CCCC · Home | $3.37 USD | +0.07 (+2.1%) | 2,354,062 | $3.23 | $3.38 | $3.21 | $3.30 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:CCCC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.37 | +0.07 | +2.1% | $3.23 | $3.38 | $3.21 | 2,354,062 | |
| $3.30 | -0.095 | -2.8% | $3.41 | $3.44 | $3.20 | 2,714,989 | |
| $3.395 | +0.185 | +5.8% | $3.25 | $3.525 | $3.23 | 4,108,477 | |
| $3.21 | +0.23 | +7.7% | $2.99 | $3.24 | $2.95 | 4,118,932 | |
| $2.98 | -0.08 | -2.6% | $3.07 | $3.07 | $2.94 | 3,179,037 | |
| $3.06 | -0.12 | -3.8% | $3.16 | $3.17 | $3.02 | 4,741,850 | |
| $3.18 | +0.01 | +0.3% | $3.13 | $3.25 | $3.12 | 1,692,802 | |
| $3.17 | +0.01 | +0.3% | $3.15 | $3.22 | $3.10 | 2,189,796 | |
| $3.16 | +0.27 | +9.3% | $2.86 | $3.20 | $2.855 | 3,689,396 | |
| $2.89 | +0.125 | +4.5% | $2.80 | $2.94 | $2.80 | 3,113,184 | |
| $2.765 | -0.015 | -0.5% | $2.78 | $2.81 | $2.695 | 2,359,300 | |
| $2.78 | +0.17 | +6.5% | $2.64 | $2.846 | $2.60 | 3,274,900 | |
| $2.61 | -0.17 | -6.1% | $2.72 | $2.795 | $2.59 | 3,094,000 | |
| $2.78 | -0.28 | -9.2% | $3.04 | $3.06 | $2.75 | 3,821,400 | |
| $3.06 | -0.10 | -3.2% | $3.16 | $3.30 | $3.05 | 1,500,400 | |
| $3.16 | +0.31 | +10.9% | $3.00 | $3.19 | $2.95 | 2,506,100 | |
| $2.85 | +0.03 | +1.1% | $2.80 | $2.88 | $2.721 | 2,827,700 | |
| $2.82 | -0.06 | -2.1% | $2.85 | $2.95 | $2.82 | 2,267,500 | |
| $2.88 | -0.11 | -3.7% | $3.02 | $3.03 | $2.79 | 2,113,100 | |
| $2.99 | +0.04 | +1.4% | $3.01 | $3.10 | $2.95 | 1,463,600 | |
| $2.95 | -0.19 | -6.1% | $3.19 | $3.33 | $2.93 | 3,384,900 | |
| $3.14 | -0.19 | -5.7% | $3.31 | $3.37 | $3.135 | 1,891,600 | |
| $3.33 | +0.20 | +6.4% | $3.16 | $3.37 | $3.13 | 2,609,200 | |
| $3.13 | +0.015 | +0.5% | $3.09 | $3.215 | $3.00 | 1,554,100 | |
| $3.115 | +0.135 | +4.5% | $3.015 | $3.16 | $2.98 | 2,776,000 | |
| $2.98 | -0.05 | -1.7% | $3.03 | $3.115 | $2.925 | 2,116,800 | |
| $3.03 | -0.05 | -1.6% | $3.03 | $3.06 | $2.88 | 2,807,600 | |
| $3.08 | -0.23 | -6.9% | $3.32 | $3.34 | $2.925 | 4,592,400 | |
| $3.31 | +0.01 | +0.3% | $3.33 | $3.42 | $3.285 | 1,357,800 | |
| $3.30 | -0.09 | -2.7% | $3.44 | $3.45 | $3.245 | 2,050,500 | |
| $3.39 | -0.025 | -0.7% | $3.43 | $3.475 | $3.38 | 1,630,900 | |
| $3.415 | -0.035 | -1.0% | $3.51 | $3.59 | $3.40 | 1,758,200 | |
| $3.45 | +0.02 | +0.6% | $3.44 | $3.53 | $3.425 | 2,320,800 | |
| $3.43 | 0.00 | 0.0% | $3.40 | $3.455 | $3.32 | 1,344,100 | |
| $3.43 | -0.08 | -2.3% | $3.46 | $3.54 | $3.41 | 1,485,400 | |
| $3.51 | +0.11 | +3.2% | $3.475 | $3.525 | $3.355 | 1,472,300 | |
| $3.40 | -0.04 | -1.2% | $3.40 | $3.41 | $3.31 | 1,167,600 | |
| $3.44 | -0.11 | -3.1% | $3.54 | $3.54 | $3.42 | 1,441,300 | |
| $3.55 | -0.21 | -5.6% | $3.72 | $3.735 | $3.55 | 2,172,400 | |
| $3.76 | +0.02 | +0.5% | $3.72 | $3.845 | $3.66 | 2,363,400 | |
| $3.74 | -0.05 | -1.3% | $3.83 | $3.85 | $3.70 | 2,227,700 | |
| $3.79 | -0.08 | -2.1% | $3.87 | $4.07 | $3.73 | 1,835,400 | |
| $3.87 | +0.16 | +4.3% | $3.68 | $3.935 | $3.66 | 2,364,100 | |
| $3.71 | -0.14 | -3.6% | $3.83 | $3.86 | $3.695 | 1,857,200 | |
| $3.85 | -0.25 | -6.1% | $4.07 | $4.10 | $3.83 | 1,824,700 | |
| $4.10 | -0.14 | -3.3% | $4.25 | $4.30 | $4.09 | 1,988,400 | |
| $4.24 | +0.04 | +1.0% | $4.17 | $4.24 | $4.03 | 1,861,700 | |
| $4.20 | +0.10 | +2.4% | $4.11 | $4.235 | $4.085 | 4,285,800 | |
| $4.10 | +0.10 | +2.5% | $3.97 | $4.14 | $3.81 | 1,752,900 | |
| $4.00 | -0.03 | -0.7% | $4.07 | $4.10 | $3.935 | 1,160,600 | |
| $4.03 | -0.18 | -4.3% | $4.14 | $4.15 | $3.832 | 2,272,700 | |
| $4.21 | +0.03 | +0.7% | $4.25 | $4.375 | $4.13 | 2,848,800 | |
| $4.18 | -0.085 | -2.0% | $4.21 | $4.30 | $4.105 | 2,878,700 | |
| $4.265 | +0.025 | +0.6% | $4.315 | $4.315 | $4.108 | 2,086,800 | |
| $4.24 | +0.16 | +3.9% | $4.07 | $4.315 | $3.895 | 3,399,000 | |
| $4.08 | +0.18 | +4.6% | $3.93 | $4.23 | $3.86 | 3,726,100 | |
| $3.90 | +0.03 | +0.8% | $3.95 | $3.995 | $3.825 | 1,956,800 | |
| $3.87 | +0.25 | +6.9% | $3.84 | $4.00 | $3.64 | 3,085,400 | |
| $3.62 | -0.11 | -2.9% | $3.75 | $3.75 | $3.60 | 1,963,800 | |
| $3.73 | +0.09 | +2.5% | $3.69 | $3.75 | $3.65 | 1,504,100 | |
| $3.64 | +0.02 | +0.6% | $3.62 | $3.72 | $3.58 | 1,823,800 | |
| $3.62 | +0.01 | +0.3% | $3.61 | $3.68 | $3.54 | 2,556,300 | |
| $3.61 | +0.11 | +3.1% | $3.57 | $3.639 | $3.47 | 2,519,600 | |
| $3.50 | +0.02 | +0.6% | $3.50 | $3.535 | $3.36 | 2,244,200 | |
| $3.48 | -0.18 | -4.9% | $3.66 | $3.66 | $3.45 | 1,949,800 | |
| $3.66 | +0.14 | +4.0% | $3.53 | $3.69 | $3.515 | 3,148,100 |
- Ticker
- BOATS:CCCC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 2, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Latest deck · Sep 25, 2026
Investor Presentation (September 2026)
Investor deck · 25 slides
Latest news
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
Oct 29, 2026
Closed $3.30 (-2.8%) on Oct 29, 2026
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Sep 25, 2026
Closed $2.98 (-1.7%) on Sep 25, 2026
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed, Refractory Multiple Myeloma Trial
Sep 4, 2026
Closed $3.76 (+0.5%) on Sep 4, 2026
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
Sep 3, 2026
Closed $3.74 (-1.3%) on Sep 3, 2026
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 11, 2026
Closed $3.87 (+6.9%) on Aug 11, 2026
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
Jun 11, 2026
Closed $3.87 (0.0%) on Jun 11, 2026
C4 Therapeutics to Participate in Upcoming Conferences
May 20, 2026
Closed $3.28 (+5.5%) on May 20, 2026
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026
Closed $3.17 (0.0%) on May 12, 2026
Decks
Investor Presentation (September 2026)
Investor deck · 25 slides · Sep 25, 2026
Investor Presentation (June 2026)
Investor deck · 26 slides · Jun 11, 2026
Investor Presentation (May 2026)
Investor deck · 23 slides · May 12, 2026
Investor Presentation (April 2026)
Investor deck · 26 slides · Apr 9, 2026
C4 Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 110 in all · newest Nov 2, 2026 · oldest 2020
- Decks
- 37 decks · latest Sep 25, 2026
Where C4 Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CCCC · Home listing | NASDAQ | United States | USD |
| BOATS:CCCC · This page | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about C4 Therapeutics, Inc.